Clinical trials: Empagliflozin
Type 2 Diabetes
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
People with newly diagnosed type 2 diabetes treated with metformin that have not reached their HbA1c target (42-64 mmol/mol) will be recruited to the study.
- Trial name
- DiaSpax (NCT05501483)
- Testing
- Pioglitazone 45 mg, Empagliflozin 25 MG, Semaglutide 7 MG
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Karolinska Institutet
Type 2 Diabetic Kidney Disease
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
This study employs a prospective, randomized, double-blind, parallel-controlled design, aiming to enroll adult participants with type 2 diabetic kidney disease (DKD) who meet the eligibility criteria.
- Trial name
- NCT07775846
- Testing
- empagliflozin, Finerenone, Mazdutide
- Where
- China
- Volunteers
- 820 people
- Sponsor
- Huijie Zhang
Diabetes Mellitus Type 2
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes.
- Trial name
- EPHIC-DIA2 (NCT06851962)
- Testing
- Metformin, Dulaglutide, Semaglutide 1.0 mg
- Where
- 3 sites in Spain
- Volunteers
- 92 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Heart Failure With Preserved Ejection Fraction (HFPEF)
This Will be a Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection Fraction
The SPECTRA-HFpEF Study is a randomized, double-blind, Phase 2 clinical study designed to evaluate and compare the biological effects of vicadrostat in combination with empagliflozin, empagliflozin alone, and spironolactone in…
- Trial name
- SPECTRA-HFpEF (NCT07857772)
- Testing
- empa plus vica, Comparator: empa 10 plus spironolactone
- Volunteers
- 200 people
- Sponsor
- Baim Institute for Clinical Research
Healthy Volunteers
Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers
- Trial name
- NCT06889350
- Testing
- HD-P023, Teneligliptin, Empagliflozin High
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Type 2 Diabetes, Dyslipidemias
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.
- Trial name
- NCT06578676
- Testing
- Empagliflozin 25 MG, Ezetimibe/Rosuvastatin 10/10mg, Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg
- Where
- South Korea
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Hyundai Pharm
Thrombosis
Antithrombotic Activities of Sotagliflozin vs. Empagliflozin
The availability of Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) has dramatically altered the management of heart failure (HF) patients, independently of their ejection fraction and glycemic status.
- Trial name
- SOTATHROMBUS (NCT06618976)
- Testing
- Sotagliflozin, Empagliflozin
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Heart Failure
A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
This is a study in adults who are in hospital for acute heart failure. The purpose of this study is to find out whether starting to take a medicine called empagliflozin soon after first being treated in hospital helps people with…
- Trial name
- NCT04157751
- Testing
- Empagliflozin
- Where
- 118 sites in United States, Belgium and 13 more
- Volunteers
- 530 people
- Sponsor
- Boehringer Ingelheim
Pre-Diabetes, Weight, Body
Prevention of Progression of Prediabetes, Obesity and CV Risk
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight.
- Conditions
- Pre-Diabetes, Weight, Body, Cardiovascular Diseases
- Trial name
- Pre-DM (NCT06446531)
- Testing
- Rybelsus Tablet, Jardiance 25Mg Tablet, Metformin
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus
Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin
This study is to evaluate pharmacokinetic drug interaction between teneligliptin and empagliflozin in healthy adults.
- Trial name
- NCT04431141
- Testing
- Teneligliptin, Empagliflozin, Teneligliptin and Empagliflozin
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Diabetes Mellitus Type 2
SGLT2 Inhibition and Left Ventricular Mass
Patients with type 2 diabetes mellitus are exposed to an excessive heart failure risk secondary to left ventricular hypertrophy and impaired diastolic filling, a condition not addressed by currently available treatments.
- Trial name
- EMPATROPHY (NCT02728453)
- Testing
- Empagliflozin, Glimepiride
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- Hannover Medical School
Congestive Heart Failure (CHF)
Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department
This study aims to evaluate whether the use of a 25 mg dose of empagliflozin compared to the 10 mg dose used would bring additional benefits in the improvement outcomes of the Kansas City Cardiomyopathy Questionnaire (KCCQ SST)…
- Trial name
- ADDEMFEP (NCT06683053)
- Testing
- empagliflozin
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- Conrado Roberto Hoffmann Filho
Diabetes Mellitus
Pharmacokinetic Evaluation of Empagliflozin
Project PI (Principal Investigator): Dr Bassam Mahfouz Ayoub, Ph.D., Lecturer of Pharmaceutical Chemistry, The British University in Egypt.
- Trial name
- NCT03059056
- Testing
- Empagliflozin 25mg
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- British University In Egypt
Atrial Fibrillation, SGLT2 Inhibitor
Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown.
- Conditions
- Atrial Fibrillation, SGLT2 Inhibitor, DC Cardioversion
- Trial name
- NCT07776054
- Testing
- SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Type2diabetes, SGLT2 Inhibitor, Urinary Tract Infection
Asymptomatic Bacteriuria, Urinalysis Abnormality at the Initiation of SGLT2 Inhibitors and UTI Risk
The SGLT2 inhibitors have changed the treatment of type 2 diabetes mellitus in recent years, especially in patients with cardiovascular or renal disease.
- Trial name
- NCT05520684
- Testing
- urine culture and urinalysis
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Trabzon Arakli Bayram Halil Public Hospital
Cardiovascular Kidney Metabolic Syndrome
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Complex pathophysiological interactions among obesity, metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system lead to poor cardiovascular-kidney-metabolic health (CKMH), which is a major determinant…
- Trial name
- DASH-CKMH (NCT07188545)
- Testing
- Intervention, Active Comparator
- Where
- United States
- Volunteers
- 23,280,000 people
- Sponsor
- Ohio State University
Acute Kidney Injury
Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors
To investigate the potential of preoperative initiation (3 days) and perioperative continuation (until day 2 after surgery) of empagliflozin(sodium glucose co transporter 2 inhibitor(SGLT-2i)) 10 mg daily to reduce the acute…
- Trial name
- MERCURI (NCT06825156)
- Testing
- Empagliflozin 10 MG
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Heart Transplant, Cardiovascular Disease
Randomized Trial of SGLT2i in Heart Transplant Recipients
Heart transplant (HTx) is an established therapy for advanced heart disease that restores quality of life and improves survival.
- Conditions
- Heart Transplant, Cardiovascular Disease, Kidney Disease
- Trial name
- NCT06625073
- Testing
- Empagliflozin
- Where
- 6 sites in United States
- Volunteers
- 200 people
- Sponsor
- VA Office of Research and Development
Heart Failure
ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling
This study aimed to compare the effects of ARNI monotherapy versus combined ARNI and SGLT2 inhibitor therapy on Mitral Remodeling Index (MRIx) and Functional mitral regurgitation (FMR) remodeling in patients with heart failure…
- Trial name
- NCT07379788
- Testing
- Sacubitril/Valsartan 49 MG-51 MG Oral Tablet [ENTRESTO], Empagliflozin10Mg Tab
- Where
- Saudi Arabia
- Volunteers
- 180 people
- Sponsor
- Rehab Werida
Congenital Heart Disease
SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
Some people are born with a birth defect where they only have one functioning ventricle (lower chamber) in their heart. This condition can be initially managed with a Fontan operation, but there is a risk of developing Fontan…
- Trial name
- EMPA-HEART-3 (NCT06955260)
- Testing
- Empagliflozin 10 mg
- Where
- 2 sites in Canada
- Volunteers
- 410 people
- Sponsor
- Subodh Verma